• ホーム
  • 活動の目的
  • 参加企業
  • 活動の成果
  • お問い合わせ

活動の成果

論文発表

  1. 北口隆:ヒトiPS細胞由来心筋細胞と多電極アレイシステムを用いた薬剤誘発性QT間隔延長および催不整脈リスク予測評価法の検討.千葉大学大学院薬学研究院学位論文, (2017)
  2. Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Tanaka K, Takahashi E, Miyamoto K, Morimura A, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Shinozawa T, Saito F, Kunimatsu T: CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information. Regul. Toxicol. Pharmacol., 88 (2017) 238-251.
  3. Kitaguchi T, Moriyama Y, Taniguchi T, Maeda S, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Miyamoto N: CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes. J Pharmacol. Toxicol. Methods, 85 (2017) 73-81.
  4. Takasuna K, Asakura K, Araki S, Ando H, Kazusa K, Kitaguchi T, Kunimatsu T, Suzuki S, Miyamoto N: Complehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi Heart initiative. J. Pharmacol. Toxicoll Methods, 83 (2017) 42-54.
  5. 宮本 憲優:ヒト iPS 細胞由来分化細胞の安全性薬理試験への応用.実験医学, 34 (2016) 557-563.
  6. Araki T, Iwazaki N, Ishiguro N, Sakamoto A, Nagata K, Ohbuchi M, Moriguchi H, Motoi M, Shinkyo R, Homma T, Sakamoto S, Iwase Y, Ise R, Nakanishi Y, Uto M, Inoue T: Requirements for human iPS cell-derived hepatocytes as an alternative to primary human hepatocytes for assessing absorption, distribution, metabolism, excretion and toxicity of pharmaceuticals. Fundamental Toxicol. Sci., 3 (2016) 89-99.
  7. Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Washio I, Takahashi E, Miyamoto K, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Kunimatsu T: CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability. Regul. Toxicol. Pharmacol., 77 (2016) 75-86.
  8. Kitaguchi T, Moriyama Y, Taniguchi T, Ojima A, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Morita M, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Tanaka K, Washio I, Miyamoto N, CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia ?Effects of 7 reference compounds at 10 facilities?. J. Pharmacol. Toxicoll Methods, Vol.78 (2016) 93-102.
  9. Asakura K, Hayashi S, Ojima A, Taniguchi T, Miyamoto N, Nakamori C, Nagasawa C, Kitamura T, Osada T, Honda Y, Kasai C, Ando H, Kanda Y, Sekino Y, Sawada K: Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. J. Pharmacol. Toxicoll Methods, 75 (2015) 17-26.
会員専用 ログイン
  • Japan iPS Cardiac Safety Assessment (JiCSA)
  • スコットランド国際開発庁からのご紹介
  • 中高生が主役の科学研究所
Page Top